Orient Competitors

Stocks . Taiwan . 
Stock . Orient Europharma Co
4120 Stock  TWD 44.85  0.40  0.90%   
Orient Europharma competes with Senhwa Biosciences, Medigen Biotechnology, Bionime Corp, and Maxigen Biotech; as well as few others. The company operates under Healthcare sector and is part of Drug Manufacturers-Specialty & Generic industry. Analyzing Orient Europharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Orient Europharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Orient Europharma Correlation with its peers.

Orient Europharma vs Maxigen Biotech Correlation

Very good diversification

The correlation between Orient Europharma Co and 1783 is -0.27 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Orient Europharma Co and 1783 in the same portfolio, assuming nothing else is changed.

Moving against Orient Stock

  0.624174 OBI Pharma SplitPairCorr
  0.464157 Taigen BiopharmaceuticaPairCorr
Hype
Prediction
LowEstimatedHigh
43.8344.8545.87
Details
Intrinsic
Valuation
LowRealHigh
43.9945.0146.03
Details
Naive
Forecast
LowNextHigh
43.0244.0445.06
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
43.6844.4645.25
Details

Orient Europharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Orient Europharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Orient and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Orient Europharma does not affect the price movement of the other competitor.

High positive correlations

6657
+ 0.85
6492
4737
+ 0.84
1752
1783
+ 0.65
6492
1783
+ 0.58
3176
1783
+ 0.5
6657
6610
+ 0.47
6657
  

High negative correlations

1752
- 0.83
3176
4737
- 0.72
3176
1783
- 0.71
1752
1783
- 0.68
4737
1752
- 0.43
6492
6610
- 0.35
3176

Risk-Adjusted Indicators

There is a big difference between Orient Stock performing well and Orient Europharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Orient Europharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Orient Europharma Competitive Analysis

The better you understand Orient Europharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Orient Europharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Orient Europharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
4120 6492 6657 7754 3176 1752 4737 6610 1783
 0.90 
 44.85 
Orient
 3.44 
 59.00 
Senhwa
 3.33 
 55.80 
Energenesis
 0.90 
 49.75 
7754
 0.30 
 32.75 
Medigen
 0.41 
 36.95 
Nang
 2.41 
 55.30 
Bionime
 1.22 
 20.20 
TWi
 1.48 
 46.70 
Maxigen
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Somewhat reliable
Very steady
Market Performance
(90 Days Performance)
Weakest
Good
Fair
Mild
Fair
Weakest
Weakest
Soft
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Small
Unknown
Unknown
Small
Unknown
Low
Unknown
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Hold
Strong Sell
Hold
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Hold
Current Ratio
N/A
38.14
N/A
N/A
N/A
N/A
1.18
N/A
7.81
Net Asset
9.4 B
N/A
N/A
N/A
8.2 B
N/A
4.56 B
N/A
1.27 B
Profit Margin
-0.0197
N/A
N/A
N/A
-0.0804
N/A
0.0454
N/A
0.19
EBITDA
313.89 M
(373.96 M)
N/A
N/A
1.35 B
N/A
248.29 M
N/A
130.56 M
Operating Margin
-0.0086
N/A
N/A
N/A
0.0172
N/A
0.0548
N/A
0.16
Current Valuation
5.9 B
9.33 B
N/A
N/A
2.9 B
N/A
6.7 B
N/A
3.32 B
Price To Book
1.07
5.03
N/A
N/A
2.01
N/A
2.31
N/A
3.24
Retained Earnings
N/A
N/A
N/A
N/A
N/A
N/A
180 M
N/A
(14 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
1.39 B
N/A
623 M
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
3.98
N/A
N/A
Beta
0.4
0.42
N/A
N/A
0.99
N/A
0.68
N/A
1.05
Number Of Employees
21
9
N/A
N/A
18
N/A
21
N/A
20
Shares Outstanding
86.75 M
89.62 M
N/A
N/A
139.45 M
N/A
60.62 M
N/A
84.7 M
Cash Flow From Operations
77.65 M
(286.34 M)
N/A
N/A
518.12 M
N/A
269.72 M
N/A
117.59 M
Annual Yield
0.0235
N/A
N/A
N/A
N/A
N/A
0.0255
N/A
0.0167
Total Debt
1.68 B
17.59 M
N/A
N/A
470.77 M
N/A
1.16 B
N/A
16.62 M
Return On Equity
-0.0268
-25.12
N/A
N/A
-0.0022
N/A
0.0467
N/A
0.0926
Z Score
0.6
N/A
N/A
N/A
5.4
N/A
2.4
N/A
N/A
Return On Asset
-0.0027
-15.79
N/A
N/A
0.0036
N/A
0.0151
N/A
0.0454
Book Value Per Share
33.54
24.95
N/A
N/A
18.24
N/A
33.68
N/A
14.75
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
935 M
N/A
63 M
Total Asset
9.4 B
N/A
N/A
N/A
8.2 B
N/A
4.56 B
N/A
1.27 B
Last Dividend Paid
0.85
N/A
N/A
N/A
N/A
N/A
2.0
N/A
N/A
Debt To Equity
N/A
0.008
N/A
N/A
N/A
N/A
100.7
N/A
1.5
Target Price
N/A
N/A
N/A
N/A
N/A
N/A
121.0
N/A
N/A
Shares Owned By Institutions
0.45
1.0
N/A
N/A
2.8
N/A
2.9
N/A
2.28
Market Capitalization
3.13 B
11.25 B
N/A
N/A
4.42 B
N/A
4.71 B
N/A
5.02 B
Price To Earning
N/A
N/A
N/A
N/A
N/A
N/A
23.69
N/A
33.55
Price To Sales
0.68
N/A
N/A
N/A
1.66
N/A
2.24
N/A
6.63
Net Income
120.17 M
(358.44 M)
N/A
N/A
(52.61 M)
N/A
87.41 M
N/A
87.67 M
Earnings Per Share
0.54
-4.38
N/A
N/A
-0.5
N/A
1.56
N/A
1.23
Shares Owned By Insiders
65.1
29.79
N/A
N/A
25.17
N/A
47.14
N/A
51.89
Revenue
4.77 B
600 K
N/A
N/A
3.92 B
N/A
1.85 B
N/A
511.98 M
Working Capital
N/A
N/A
N/A
N/A
N/A
N/A
450 M
N/A
560 M
Cash And Equivalents
N/A
2.21 B
N/A
N/A
N/A
N/A
388.32 M
N/A
390.34 M
Cash Per Share
N/A
24.67
N/A
N/A
N/A
N/A
6.76
N/A
5.62
Gross Profit
2.15 B
351 K
N/A
N/A
2.55 B
N/A
783.13 M
N/A
261.03 M
Day Typical Price
44.72
59.93
56.0
49.7
33.22
36.95
55.17
20.23
46.72
Accumulation Distribution
160.96
68871.43
202685.0
6838.85
18423.84
1118.92
9191.96
8048.32
1473.82
Daily Balance Of Power
0.8
(0.66)
0.4286
(0.20)
(0.07)
0.3
0.5417
(0.42)
(1.08)
Period Momentum Indicator
0.4
(2.10)
1.8
(0.45)
(0.10)
0.15
1.3
(0.25)
(0.70)
Rate Of Daily Change
1.01
0.97
1.03
0.99
1.0
1.0
1.02
0.99
0.99
Day Median Price
44.65
60.4
56.1
49.68
33.45
36.95
55.1
20.25
46.72
Price Action Indicator
0.4
(2.45)
0.6
(0.15)
(0.75)
0.075
0.85
(0.18)
(0.37)
Relative Strength Index
50.18
70.25
66.86
N/A
56.03
44.65
43.56
N/A
60.59
Coefficient Of Variation
(905.93)
769.57
926.1
1483.81
1098.88
(673.09)
(876.82)
2474.72
1033.58
Mean Deviation
0.8056
2.02
2.01
1.93
1.21
0.3713
1.13
2.67
0.9576
Jensen Alpha
(0.13)
0.3706
0.3543
0.182
0.1575
(0.09)
(0.17)
0.1967
0.1052
Total Risk Alpha
(0.21)
0.17
0.1009
(0.02)
0.0266
(0.12)
(0.28)
(0.14)
0.0257
Sortino Ratio
N/A
0.1208
0.1037
0.0807
0.062
N/A
N/A
0.0451
0.0542
Downside Variance
N/A
7.6
6.27
4.09
2.75
N/A
N/A
6.7
1.73
Standard Deviation
1.12
3.04
2.97
3.33
1.8
0.5028
1.47
4.41
1.37
Kurtosis
1.67
3.63
3.05
17.1
4.14
0.966
0.5149
11.87
3.69
Potential Upside
1.47
5.7
5.35
3.37
3.3
1.06
2.27
5.47
1.78
Treynor Ratio
2.08
1.43
(0.37)
0.3388
(2.25)
(0.67)
1.06
(0.30)
0.3626
Maximum Drawdown
5.44
12.24
17.79
22.67
11.21
2.15
7.86
24.76
8.45
Variance
1.25
9.22
8.83
11.09
3.25
0.2528
2.15
19.42
1.88
Market Risk Adjusted Performance
2.09
1.44
(0.36)
0.3488
(2.24)
(0.66)
1.07
(0.29)
0.3726
Risk Adjusted Performance
(0.08)
0.1019
0.086
0.0567
0.072
(0.11)
(0.08)
0.0377
0.0749
Skewness
(0.92)
0.9327
0.9398
3.37
1.13
0.7585
(0.30)
2.9
0.4144
Semi Deviation
N/A
2.21
2.08
1.75
1.41
N/A
N/A
2.31
1.1
Information Ratio
(0.17)
0.1097
0.0874
0.049
0.057
(0.27)
(0.16)
0.0265
0.052
Value At Risk
(1.91)
(3.44)
(3.84)
(3.14)
(2.67)
(0.90)
(2.46)
(3.72)
(1.59)
Expected Short fall
N/A
(2.17)
(2.51)
(2.47)
(1.28)
N/A
N/A
(4.48)
(1.06)
Downside Deviation
N/A
2.76
2.5
2.02
1.66
N/A
N/A
2.59
1.31
Semi Variance
N/A
4.89
4.33
3.08
2.0
N/A
N/A
5.32
1.21

Orient Europharma Competition Performance Charts

Five steps to successful analysis of Orient Europharma Competition

Orient Europharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Orient Europharma in relation to its competition. Orient Europharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Orient Europharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Orient Europharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Orient Europharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Orient Europharma position

In addition to having Orient Europharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Trump Equities Thematic Idea Now

Trump Equities
Trump Equities Theme
Stocks that have significantly increased in valuation since Trump was elected president of the United States. The Trump Equities theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trump Equities Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Orient Stock Analysis

When running Orient Europharma's price analysis, check to measure Orient Europharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orient Europharma is operating at the current time. Most of Orient Europharma's value examination focuses on studying past and present price action to predict the probability of Orient Europharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orient Europharma's price. Additionally, you may evaluate how the addition of Orient Europharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY